The Norwegian Precision Cancer Medicine Implementation Consortium, a landmark public-private initiative, represents a collaboration between 22 key public and private partners for promoting precision cancer medicine. Known as CONNECT, this newest initiative within the consortium represents one of four interconnected projects in this Scandinavian country that supports critical infrastructure and collaboration involving diagnostics, clinical trials, actual execution of advanced precision medicine and the use of health data for a range of important societal benefits such as for health economics analysis. Just recently, the multinational Japanese information technology and electronics company NEC joined the consortium embarking on a strategy to leverage mounting real-world data to reinforce and accelerate the firm’s personalized cancer immunotherapy efforts.
TrialSite introduces CONNECT and explores more about the implication for precision cancer care in Norway and beyond.
How many people are diagnosed with cancer in Norway annually?
30,000 and that number is growing.
What is precision cancer care?
According to the U.S. National Cancer Institute (NCI), precision med...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).